CTOs on the Move

Affinium Pharmaceuticals

www.afnm.com

 
Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.afnm.com
  • 100 University Ave
    Toronto, ON CAN M5J 1V6
  • Phone: 416.645.6600

Executives

Name Title Contact Details

Similar Companies

UDG Healthcare plc

UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services.

Mississippi Sports Medicine

Mississippis first full-service orthopaedic speciality practice. #AnyAge #AnySport #AnyInjury Just come here; weve got you covered.

Adfinitas Health

Adfinitas Health (formerly MDICS) is Marylands largest private hospitalist group of physicians, nurse practitioners and physician assistants, dedicated to providing comprehensive, cost-effective, high-quality medical care to patients in hospitals, ski...

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.